Engagement in digital and data driven health outcomes. Tangata Tiriti. Proudly neurodivergent.
Today, I received an email many others will have received after contributing to the consultation on funding for lisdexamfetamine and stimulant treatment criteria. I’m grateful to everyone who helped inform Pharmac’s decision. For me, this email means a lot. Removing the need to repeatedly justify ADHD as part of my identity—and not a condition that might disappear—saves resources in a stretched healthcare system. It also removes the fear of losing access to crucial medication. The financial barrier to accessing life-changing medication has been reduced, which will benefit many New Zealanders. While the barriers in society related to being neurodivergent may not always be obvious, they are real, and today, two major barriers have been removed. Thank you to all who contributed.
Advocacy at work. Brave wahine toa x
Chief Executive at NZ Disability Employers' Network (home of the Accessibility Tick). Helping NZ organisations to be more disability and neurodiversity inclusive.
2dI also sort confirmation from them that lisdexamfetamine would be covered by the removal of the need to renew, which they confirmed.